Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINATION: Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation
NCT06615596Phase 1Recruiting
- Sponsor
- National Center for Cardiovascular Disease
- Start
- Aug 2025
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of anticoagulant citrate dextrose solution A in Atrial fibrillation (AFib) (2 arms), sponsored by National Center for Cardiovascular Disease. Primary endpoint: Composite outcome consisting of thromboembolic events and clinically significant bleeding events at 24 months. Started Aug 2025; status: recruiting.
02
Drugs
anticoagulant citrate dextrose solution A
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT06615596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06615596.